journal article·2022-06Open access

Tuning the Hydrophilic–Hydrophobic Balance of Molecular Polymer Bottlebrushes Enhances their Tumor Homing Properties

Parathan Ramamurthi, Zhongchao Zhao, Eamonn Burke, Nicole F. Steinmetz, Markus Müllner

Advanced Healthcare Materials· Volume 11· Issue 12

Abstract

Abstract Nanoparticle (NP)‐based drug delivery systems are promising in anticancer therapy, capable of delivering cargo with superior selectivity and achieving enhanced tumor accumulation compared to small‐molecule therapeutics. As more efforts are being devoted to NP development, molecular polymer bottlebrushes (MPBs) have gained attention as a potential drug delivery vehicle. To date, the influence of various MPB parameters such as size, shape, and surface charge in determining tumor penetrability have been systematically probed. However, the role of amphiphilicity, specifically the hydrophilic–hydrophobic balance, remains unexplored. In this study, a series of MPBs are employed with varied hydrophobicity levels to reveal a dependence between MPB composition, cell association, and tumor homing. The data indicates that increasing levels of hydrophobicity in MPBs (to a certain level) demonstrate only marginal effects in vitro but reveals enhanced tumor homing in a mouse model of ovarian cancer in vivo, where more hydrophilic MPBs exhibit low tissue deposition and low tumor homing. In contrast, more hydrophobic MPBs show significant tumor accumulation and homing due to their engineered hydrophobicity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Polymer Surface Interaction Studies · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Centre for Polymers and Colloids School of Chemistry The University of Sydney Sydney NSW 2006 Australia

Department of NanoEngineering University of California, San Diego 9500 Gilman Dr. La Jolla CA 92039 USA

Center for Nano‐ImmunoEngineering University of California, San Diego 9500 Gilman Dr. La Jolla CA 92039 USA

Department of Bioengineering University of California, San Diego 9500 Gilman Dr. La Jolla CA 92039 USA

Department of Radiology University of California, San Diego 9500 Gilman Dr. La Jolla CA 92039 USA

Moores Cancer Center Institute for Materials Discovery and Design University of California, San Diego 9500 Gilman Dr. La Jolla CA 92039 USA

The University of Sydney Nano Institute (Sydney Nano) The University of Sydney Sydney NSW 2006 Australia

Funding

University of Sydney

References (50)

Show source-provided references
1. 10.1016/j.cbi.2018.04.01910.1016/j.cbi.2018.04.019 ↗
2. 10.1021/acs.biomac.6b0153310.1021/acs.biomac.6b01533 ↗
3. 10.1016/j.ejpb.2008.11.01010.1016/j.ejpb.2008.11.010 ↗
4. 10.1016/j.actbio.2018.11.05010.1016/j.actbio.2018.11.050 ↗
5. 10.1039/D0PY00653J10.1039/D0PY00653J ↗
6. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
7. 10.1186/s13045-021-01096-010.1186/s13045-021-01096-0 ↗
8. 10.1016/j.addr.2014.03.00110.1016/j.addr.2014.03.001 ↗
9. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
10. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
11. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
12. 10.1021/mp300684a10.1021/mp300684a ↗
13. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
14. 10.1002/anie.20110444910.1002/anie.201104449 ↗
15. 10.1039/C8TB00038G10.1039/C8TB00038G ↗
16. 10.1038/nnano.2010.5810.1038/nnano.2010.58 ↗
17. 10.1039/C8TB03034K10.1039/C8TB03034K ↗
18. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
19. 10.1021/mp900022m10.1021/mp900022m ↗
20. 10.1021/nl06274310.1021/nl062743 ↗
21. 10.2147/IJN.S21593510.2147/IJN.S215935 ↗
22. 10.1021/ja210890510.1021/ja2108905 ↗
23. 10.1021/jp805190610.1021/jp8051906 ↗
24. 10.1039/C7NR07898F10.1039/C7NR07898F ↗
25. 10.1021/acsmacrolett.0c0089010.1021/acsmacrolett.0c00890 ↗
26. 10.1039/D0SC02611E10.1039/D0SC02611E ↗
27. 10.1021/ma102150610.1021/ma1021506 ↗
28. 10.1021/nn505125f10.1021/nn505125f ↗
29. 10.1039/C4BM00458B10.1039/C4BM00458B ↗
30. 10.1039/C8PY00703A10.1039/C8PY00703A ↗
31. 10.1016/j.polymer.2017.02.00110.1016/j.polymer.2017.02.001 ↗
32. 10.1002/marc.20210013810.1002/marc.202100138 ↗
33. 10.1016/j.polymer.2016.03.07610.1016/j.polymer.2016.03.076 ↗
34. 10.1002/macp.20160008610.1002/macp.201600086 ↗
35. 10.1021/jacs.6b0578710.1021/jacs.6b05787 ↗
36. 10.1021/ja502011g10.1021/ja502011g ↗
37. 10.1038/ncomms646010.1038/ncomms6460 ↗
38. 10.1002/anie.20171187810.1002/anie.201711878 ↗
39. 10.1021/nn305434710.1021/nn3054347 ↗
40. 10.1021/ma701970t10.1021/ma701970t ↗
41. 10.1039/b816603j10.1039/b816603j ↗
42. 10.1039/C6NR08654C10.1039/C6NR08654C ↗
43. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
44. 10.1039/C6CC00447D10.1039/C6CC00447D ↗
45. 10.3390/ijms1806124910.3390/ijms18061249 ↗
46. 10.1016/0304-4165(93)90105-H10.1016/0304-4165(93)90105-H ↗
47. 10.1146/annurev-pharmtox-010611-13462310.1146/annurev-pharmtox-010611-134623 ↗
48. 10.1016/j.jconrel.2013.09.01310.1016/j.jconrel.2013.09.013 ↗
49. 10.1016/S0024-3205(99)00068-510.1016/S0024-3205(99)00068-5 ↗
50. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗